Ibrutinib covalently binds to cysteine-481 within the active site of BTK, blocking the signal transduction from the B-cell receptor (BCR) and, thus, impairing CLL cells survival and proliferation (reviewed in [8]). This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.